Targeted therapies against these pathways, such as cetuximab (anti-EGFR), encorafenib (BRAF inhibitor), and bevacizumab (anti-VEGF), have been successfully administered for treating metastatic CRC patients. The gene discussed is EGFR; the disease is colorectal carcinoma.